Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The role of DPF2 stability in SMARCB1-deficient cancers

Award Number: F31CA278008
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 09/01/2023
PERIOD OF PERFORMANCE END DATE: 11/14/2026

Group Awards By:

View Award Description

The role of DPF2 stability in SMARCB1-deficient cancers - PROJECT SUMMARY Rhabdoid tumors are one of the most aggressive and lethal cancers in pediatric oncology with overall 5-year survival rates of ~20-25%. Loss of SMARCB1 is the primary recurrent genetic alteration found in over 90% of cases. Recent advances have implicated SMARCB1 loss in a number of other cancers broadly referred to as SMARCB1-deficient cancers. SMARCB1 is a critical component of the BAF chromatin remodeling complex, a complex which controls gene transcription by positioning nucleosomes at gene regulatory regions. Targeted localization of the BAF complex to enhancers has largely been attributed to SMARCB1, yet no domain has been identified on SMARCB1 that is able to recognize and bind specific histone marks. Instead SMARCB1 is only able to nonspecifically bind to nucleosomes. This raises a key question: how does the BAF complex recognize regulatory regions such as enhancers and bind. Recent work has shown that deletion of SMARCB1 depletes an adjacent BAF subunit, DPF2, which is able to recognize and bind histone marks associated with enhancers. Re- expression of SMARCB1 in a SMARCB1-deficient cell line leads to a robust accumulation of DPF2. The histone reader protein, DPF2, has previously been implicated in the recruitment of the BAF complex to regulatory regions. Through deep mutational scanning of SMARCB1, we have identified four missense mutations in SMARCB1 that seem to mimic an oncogenic loss of function nonsense mutation. These residues are predicted to directly interact with DPF2, which suggests SMARCB1 mediates its tumor suppressor role at least partially through its interaction with DPF2. Moreover, we have identified a novel tumor suppressor role of DPF2 in the context of constitutive overexpression in two SMARCB1-deficient cancers cell lines. For this reason, we hypothesize that depletion of DPF2 is required in SMARCB1-deficient cancers. In Aim 1, I will test the hypothesis that reduced DPF2 association with the BAF complex is driving this observed loss of function phenotype by assessing the phenotypic, structural, and regulatory effects of each proposed SMARCB1 mutant. In Aim 2, I will test the hypothesis that stabilization of DPF2 may be a promising therapeutic strategy to restore transcription normalcy despite the loss of SMARCB1. In this aim I will characterize the phenotypic, structural, and regulatory consequences of DPF2 overexpression in SMARCB1-deficent cell lines and determine if this is occurring through either a BAF-dependent or BAF-independent mechanism. Together these aims will provide fundamental insight into the mechanisms through which SMARCB1 exerts its tumor suppressor function, as well as expand our understanding of DPF2 in SMARCB1-deficient cancers as a potential therapeutic target.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $49,538 )
2026	2026	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Research Manpower	000	3	12/10/2025	NON-COMPETING CONTINUATION	$49,538
														Subtotal = $49,538

Issue Date FY: 2025 ( Subtotal = $49,538 )
2025	2025	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Research Manpower	000	2	11/1/2024	NON-COMPETING CONTINUATION	$48,974
2025	2025	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Research Manpower	001	2	5/22/2025	NON-COMPETING CONTINUATION	$564
														Subtotal = $49,538

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Research Manpower	000	1	5/24/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $47,694 )
2023	2023	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Research Manpower	002	1	7/10/2023	NEW	$0
2023	2023	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Research Manpower	001	1	7/10/2023	NEW	$0
2023	2023	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Research Manpower	000	1	7/10/2023	NEW	$47,694
														Subtotal = $47,694

Grand Total All Awards = $146,770

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The role of DPF2 stability in SMARCB1-deficient cancers

Award Number: F31CA278008

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 09/01/2023

PERIOD OF PERFORMANCE END DATE: 11/14/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer